AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02440646 — intervention group
Intervention type: RADIATION
Intervention: Coronary computed tomography angiography
Description: The coronary arteries will be visualized with the MSCT scan CT 5000 Ingenuity (Philips, The Netherlands) or systems from any other vendors.
Study NCT02440646 — intervention group
Intervention type: RADIATION
Intervention: Quantitative coronary angiography, intravascular imaging with percutaneous intervention
Description: Coronaries will be shot with Artis zee (Siemens, Germany) or systems from any other vendors. In case if necessary the procedure will be delayed for intravascular imaging (FFR, QFR, OCT, IVUS, VH-IVUS) and/ or percutaneous intervention (with implantation of the medical device).
Study NCT03439098 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fermented Codonopsis lanceolata 525mg
Description: Fermented Codonopsis lanceolata 525mg daily for 8 weeks
Study NCT03439098 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fermented Codonopsis lanceolata 1050mg
Description: Fermented Codonopsis lanceolata 1050mg daily for 8 weeks
Study NCT03439098 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily for 8 weeks
Study NCT00932659 — intervention group
Intervention type: DEVICE
Intervention: continuous cardiac monitoring device (REVEAL, Medtronic)
Description: hemodialysis patients without a prior history of cardiac arrhythmias will undergo implantation of a continuous cardiac monitoring device, and will undergo 6 months of follow-up
Study NCT04488978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan/Amlodipine
Description: QID
Study NCT03285659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention: INDI Implementation
Description: Implementation of a collaborative care model in the context of primary care to manage depression
Study NCT04488978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan/Amlodipine
Description: QID
Study NCT02750553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0534
Study NCT02750553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02867241 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Early
Description: Participants will receive an intervention which includes motivational interviewing, biochemical feedback, air quality feedback, phone calls, and social media
Study NCT02867241 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral Late
Description: After the close of the study, Participants will receive an intervention which includes motivational interviewing, biochemical feedback, air quality feedback, phone calls, and social media
Study NCT06014970 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health and Wellness Curriculum
Description: The curriculum includes instructions, activities, and lessons on mindfulness, neurobiology, meditation, positive thinking, movement, and nutrition.
Study NCT02206087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PER977
Description: Reversal of heparin-induced anticoagulation
Study NCT02206087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Reversal of heparin-induced anticoagulation
Study NCT02206087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin Sodium
Study NCT02604706 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NADA Acupuncture
Description: NADA-acupuncture was delivered in three phases: (1) one treatment each day during the first of a total of five weeks; (2) three treatments each week during the following two weeks; (3) two treatments each week during the two remaining weeks. each session consisted of approximately 40 minutes with acupuncture at five ear points called Sympathetic, Shen Men, Kidney, Liver and Lung, which are believed to be the best points for substance abuse patients. Acupuncture was administered to both ears using stainless steel needles. NADA-acupuncture were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
Study NCT02604706 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LP acupuncture
Description: The LP-acupuncture was delivered in two phases: (1) three treatments each week during the two first weeks; (2) two treatments each week for two weeks. each session consisted of approximately 40 minutes with acupuncture at five ear points called Sympathetic, Shen Men, Kidney, Liver and Lung, which are believed to be the best points for substance abuse patients. Acupuncture was administered to both ears using stainless steel needles. LP-acupuncture were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
Study NCT02604706 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation
Description: Relaxation consisted of listening to soft music in a quiet room with dampened light and was delivered to match the amount and phases of the LP-acupuncture. Relaxation were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
Study NCT01742234 — intervention group
Intervention type: PROCEDURE
Intervention: Organ Donation
Description: People in this study will donate either a lung or kidney
Study NCT04049240 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device: low-flow nasal oxygenation (LFNO) 18<BMI<30 kg/m2
Description: Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
Study NCT04049240 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device: low-flow nasal oxygenation (LFNO) 30≤BMI<35 kg/m2
Description: Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
Study NCT04049240 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device: low-flow nasal oxygenation (LFNO) BMI≥35 kg/m2
Description: Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
Study NCT04049240 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device: High-flow nasal oxygenation (HFNO) 18<BMI<30 kg/m2
Description: Experimental HFNO: O2 flow 40 L/min, FiO2 40%
Study NCT04049240 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device: High-flow nasal oxygenation (HFNO) 30≤BMI<35 kg/m2
Description: Experimental HFNO: O2 flow 40 L/min, FiO2 40%
Study NCT04049240 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device: High-flow nasal oxygenation (HFNO) BMI≥35 kg/m2
Description: Experimental HFNO: O2 flow 40 L/min, FiO2 40%
Study NCT03148483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early PT
Description: Women will receive conventional non-surgical periodontal therapy (PT), consisting of prophylactic dental polishing to remove the sticky bacterial film that forms on the teeth over time, scaling and root planing, as necessary throughout pregnancy, up to delivery
Study NCT03148483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delayed PT
Description: Women will receive conventional non-surgical PT delayed until after delivery.
Study NCT03148483 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Delayed PT
Description: Women will receive conventional non-surgical PT delayed until after delivery.
Study NCT03148483 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortified Milk
Description: participants will be advised to take two servings of a powdered milk-based drink enriched with calcium and vitamin D daily during breakfast and afternoon snack or supper to avoid concomitant intake of the prenatal iron supplements routinely prescribed for consumption with hot main meals (e.g. lunch or dinner). Women will be advised to consume 20 g of commercially available semi-skimmed milk powder (provided by the study) and one sachet with 500 IU of vitamin D3 and 1,2 g of a calcium supplement from milk extract (300 mg of calcium) twice a day.
Study NCT03148483 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Plain Milk
Description: Women will be advised to consume 20 g of commercially available semi-skimmed milk powder (provided by the study) and one sachet with flour (placebo).
Study NCT03148483 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plain Milk
Description: Women will be advised to consume 20 g of commercially available semi-skimmed milk powder (provided by the study) and one sachet with flour (placebo).
Study NCT03163836 — intervention group
Intervention type: PROCEDURE
Intervention: double valve replacement
Description: After median sternotomy, cardiopulmonary bypass was established via bicaval and aortic cannulation. After cross-clamping of the aorta and cardioplegia, mitral and aortic replacement were performed. Supplementary procedures such tricuspid annuloplasty, ascending aorta replacement and coronary artery bypass grafting were performed as required. The left atrial appendage was excised to avoid thrombus formation.
Study NCT03163836 — intervention group
Intervention type: PROCEDURE
Intervention: surgical ablation
Description: Both left and right atrial ablation were performed using a bi-polar radiofrequency ablation clamp.
Study NCT02072278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg
Study NCT02072278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine 20 mg
Study NCT02072278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram 15 mg
Study NCT02072278 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03453424 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TEA+DEX
Description: intra and post operative TEA infusion of (bupivacaine +fentanyl 2 mic/ ml+ dexmedetomidine 0.5 mic/ ml) Under strict aseptic precautions thoracic epidural was performed using a 16 gauge,Tuhy epidural needle by a paramedian approach. T8-T9 inter space was chosen for the injection. Skin at insertion site was anesthetized by 3 ml of lidocaine 1%, the epidural space was identified by the loss of resistance technique, the catheter was introduced approximately 2-4 cm into the epidural space, epidural test dose consisted of 3 ml of lidocaine 2 % with 1: 200,000 adrenaline.
Study NCT03453424 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TEA
Description: Under strict aseptic precautions thoracic epidural was performed using a 16 gauge,Tuhy epidural needle by a paramedian approach. T8-T9 interspace was chosen for the injection. Skin at insertion site was anesthetized by 3 ml of lidocaine 1%, the epidural space was identified by the loss of resistance technique, the catheter was introduced approximately 2-4 cm into the epidural space, epidural test dose consisted of 3 ml of lidocaine 2 % with 1: 200,000 adrenaline.~then, intra and post operative TEA infusion of bupivacaine 0.125%+fentanyl 2 mic/ ml.
Study NCT00815022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine/fentanyl/morphine
Description: Hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg
Study NCT00815022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine/fentanyl/morphine
Description: Hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg
Study NCT06442163 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVAPS study was performed within 1 week of the CPAP titration attempt failure, using the auto-titrating EPAP (AE), the OmniLab Advanced +, System One device (Philips Respironics, Murrysville, PA, U.S.
Description: After attending an educational session (in the presence of a family member) with hands-on training, the AVAP -AE devices were provided to the patients.~During the study, one month after AVAPS -AE initiation, patients had direct immediate access to medical and technical support through phone contact during daytime working hours.
Study NCT01801423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Hydroxyurea will be prescribed as an investigational therapy by the treating physician. Recommended guidelines for titration of hydroxyurea to maximal tolerated dose are below. The study intervention will include hydroxyurea to begin at \~20 mg/kg/day (range 17.5 - 26 mg/kg/day). No dose escalation will occur as this dose was shown to have some efficacy in infants with SCA and was associated with rare myelosuppression.(1)
Study NCT02490605 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: occlusal plate group
Description: occlusal plate with criteria for occlusal stability (simultaneous, bilateral contacts with an absence of interference in the canine and anterior guides
Study NCT02490605 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic exercises
Description: The exercise will consist of the movement of repeatedly opening the mouth with the tongue cleaving to the roof of the mouth 3 times per day with each period consists of of 3 sets with 15 repetitions
Study NCT02490605 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic exercises
Description: The exercise will consist of the movement of repeatedly opening the mouth with the tongue cleaving to the roof of the mouth 3 times per day with each period consists of of 3 sets with 15 repetitions
Study NCT01540578 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02475018 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk fortified with plant sterol esters
Description: 250mL of Shuhua milk fortified with plant sterol esters(with plant sterol esters 262mg/100mL) has been taken twice per day. 500mL of Shuhua milk in total has been taken per day during the 60-days intervention.
Study NCT02475018 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Plain milk
Description: 250mL of placebo milk (plain milk) has been taken twice per day. 500mL of plain milk in total has been taken per day during the 60-days intervention.
Study NCT02654899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06815345
Description: PF-06815345 will be administered as a liquid dosage formulation
Study NCT02654899 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02654899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06815345
Description: PF-06815345 will be administered as either solid dosage formulation or liquid dosage formulation
Study NCT02197143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole
Description: 40 mg esomeprazole in 150 ml normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
Study NCT02197143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine
Description: 50mg Ranitidine in 150 ml normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
Study NCT02197143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrotalcid
Description: 150 ml only normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
Study NCT03822195 — intervention group
Intervention type: PROCEDURE
Intervention: Carotid endoarterectomy
Description: Surgical removal of carotid bifurcation plaque and arterial repair (direct suture or patch)
Study NCT00733226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OM-85 BV (Broncho-Vaxom)
Description: 3.5 mg capsule, 1 capsule per day for first 10 day of the month, for 3 months
Study NCT00733226 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OM-85 BV (placebo)
Description: 3.5 mg oral placebo capsule, 1 placebo capsule per day for first 10 days of the months for 3 months
Study NCT01703845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium (high dose) + Olodaterol
Description: Tiotropium + Olodaterol solution for inhalation
Study NCT01703845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium (low dose) + Olodaterol
Description: Tiotropium + Olodaterol solution for inhalation
Study NCT00848393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl (High Dose)
Description: Fentanyl (High Dose) 25 mcg/kg in two divided doses. Half-dose will be given at induction and the second half-dose given prior to incision.
Study NCT00848393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl (Low Dose)
Description: Fentanyl (Low Dose) 10 mcg/kg in two divided doses. Half-dose will be given at induction and the second half-dose given prior to incision.
Study NCT00848393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl (Low Dose) + Dexmedetomidine
Description: Fentanyl (Low Dose) + Dexmedetomidine. Dexmedetomidine at 1mcg/kg loading dose over 10 minutes, followed by an infusion at a rate of 0.5mcg/kg/hr. In addition, this group will receive a total of 10 mcg/kg Fentanyl (Low Dose). Half the dose will be given at induction and the second half before incision.
Study NCT00766142 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Study NCT00766142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT00766142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study NCT00766142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study NCT00766142 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study NCT00766142 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Study NCT00575367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AzaSite (azithromycin ophthalmic solution)
Description: One drop ophthalmic solution at Visit 2
Study NCT00575367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vigamox (moxifloxacin hydrochloride ophthalmic solution)
Description: One drop ophthalmic solution at Visit 2
Study NCT01935596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaïne
Description: spinal anesthesia.
Study NCT01935596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lévobupivacaïne
Study NCT01750086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide 40-mcg subcutaneous injection
Study NCT01750086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab Injection
Description: One-time Denosumab injection
Study NCT01750086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate Oral Tablet
Description: weekly alendronate for 8 weeks
Study NCT02014415 — intervention group
Intervention type: PROCEDURE
Intervention: Liver Biopsy (Biopsy Group Only)
Description: A percutaneous (needle) liver biopsy will be performed on subjects in the Liver Biopsy Group, in Year 1 and Year 5 of the study.
Study NCT01084239 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cardiac Computed Tomography
Description: A contrast enhanced cardiac CT was performed in addition to standard evaluation. Reconstructed data sets were evaluated for the presence of coronary artery calcium, coronary atherosclerotic plaque and stenosis, LV function and incidental findings.
Study NCT00799747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4017
Description: ascending single doses (start dose 2 mg), oral suspension
Study NCT00799747 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT03692689 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCT200
Description: Recombinant Anti-EGFR Monoclonal Antibody（SCT200）
Study NCT00730847 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix
Description: Three doses of Cervarix administered intramuscularly in the deltoid region, according to a 0, 1, 6-month vaccination schedule.
Study NCT01124214 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endomicroscopy
Description: endomicroscopy scope lens has capability to optically evaluate mucosa/submucosa as a microscope
Study NCT02428218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Description: enteric-coated microtablets
Study NCT02428218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: enteric-coated microtablets
Study NCT00555646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-10 (rose bengal disodium 0.001%)
Description: Treatment plaque area 1: PH-10 with 544 nm LED light illumination.
Study NCT00555646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-10 (rose bengal disodium 0.001%)
Description: Treatment plaque area 2: PH-10 with ambient light illumination.
Study NCT00555646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control
Description: No treatment control.
Study NCT02396953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide PRF
Study NCT04517877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caring Response App
Description: Participants will receive the Caring Light mobile app containing the coping skills training.
Study NCT04517877 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Educational/Resources Program
Description: Participants will receive a traditional educational/resources program, containing a workbook and online resources.
Study NCT00982540 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: caspofungin as preemptive antifungal therapy
Description: 70 mg day 1 followed by 50 mg/day IV